1. Home
  2. BENF vs SCLX Comparison

BENF vs SCLX Comparison

Compare BENF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beneficient

BENF

Beneficient

HOLD

Current Price

$3.25

Market Cap

52.6M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.48

Market Cap

48.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BENF
SCLX
Founded
2003
2011
Country
United States
United States
Employees
55
34
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.6M
48.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BENF
SCLX
Price
$3.25
$6.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.5K
92.4K
Earning Date
02-17-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$122.52
Revenue Next Year
$30.01
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$4.09
52 Week High
$9.96
$34.27

Technical Indicators

Market Signals
Indicator
BENF
SCLX
Relative Strength Index (RSI) 46.53 39.05
Support Level $3.15 $6.20
Resistance Level $3.56 $8.18
Average True Range (ATR) 0.19 1.38
MACD 0.00 -0.32
Stochastic Oscillator 39.53 1.16

Price Performance

Historical Comparison
BENF
SCLX

About BENF Beneficient

Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: